Cargando…
Recent advances in triple negative breast cancer: the immunotherapy era
BACKGROUND: Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheless, despi...
Autores principales: | Marra, Antonio, Viale, Giulia, Curigliano, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507064/ https://www.ncbi.nlm.nih.gov/pubmed/31068190 http://dx.doi.org/10.1186/s12916-019-1326-5 |
Ejemplares similares
-
Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021) -
Immunotherapy in triple-negative breast cancer: A literature review and new advances
por: Valencia, Guillermo Arturo, et al.
Publicado: (2022) -
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020) -
Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor
por: Rao, Zhou-Zhou, et al.
Publicado: (2023) -
Why natural killer cells in triple negative breast cancer?
por: Abdel-Latif, Mustafa, et al.
Publicado: (2020)